LAURA
For stage III lung cancers with an EGFR mutation, a targeted pill after chemoradiation cut progression by more than 80%.
216 patients. PFS 39.1 vs 5.6 months (HR 0.16); OS immature but favourable. FDA approval September 2024. Replaces durvalumab consolidation in EGFR-mutant stage III disease.
Setting
Unresectable stage III EGFR-mutant NSCLC after chemoradiation: osimertinib until progression vs placebo
Phase
Phase 3
Sponsor
AstraZeneca
Registry
Headline result
PFS HR 0.16.
Reported
2024
Enrolled
216
Replication
Single pivotal trial; consistent with ADAURA in showing large EGFR-TKI benefit after local therapy. OS immature.
In plain words
What these results mean for people, not percentages
Progression-free survival (BICR)primarysurrogate endpoint
- Median 39.1 vs 5.6 months with Osimertinib compared with Placebo; about 33.5 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 84 percent lower chance of the event at any given time (hazard ratio 0.16, likely range 0.1 to 0.24).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Unresectable stage III EGFR-mutant NSCLC after chemoradiation: osimertinib until progression vs placebo. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (EGFR); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
216 participants enrolled.
Progression-free survival (BICR)primary
HR 0.16 (0.1–0.24) · p <0.001
Osimertinib
39.1 mo
Placebo
5.6 mo
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (BICR)primary | Osimertinib | 143 | 39.1 months | 0.16 (0.1–0.24) | <0.001 | link |
| Placebo | 73 | 5.6 months |
Replication
Single pivotal trial; consistent with ADAURA in showing large EGFR-TKI benefit after local therapy. OS immature.